By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Rating today affirmed its "A-" issuer default rating for Thermo Fisher Scientific, following the firm's announcement that it plans to acquire allergy and autoimmune diagnostics firm Phadia for €2.47 billion ($3.5 billion).

The ratings apply to $4.3 billion of debt outstanding as of April 2. The ratings outlook on Thermo Fisher is "Stable," Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.